<?xml version='1.0' encoding='utf-8'?>
<document id="26244068"><sentence text="Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a &quot;special population&quot;?" /><sentence text="A substantial proportion of individuals with chronic hepatitis C virus (HCV) are co-infected with human immunodeficiency virus (HIV)" /><sentence text=" Co-infected individuals are traditionally considered as one of the &quot;special populations&quot; amongst those with chronic HCV, mainly because of faster progression to end-stage liver disease and suboptimal responses to treatment with pegylated interferon alpha and ribavirin, the benefits of which are often outweighed by toxicity"><entity charOffset="260-269" id="DDI-PubMed.26244068.s3.e0" text="ribavirin" /></sentence><sentence text=" The advent of the newer direct acting antivirals (DAAs) has given hope that the majority of co-infected individuals can clear HCV" /><sentence text=" However the &quot;special population&quot; designation may prove an obstacle for those with co-infection to gain access to the new agents, in terms of requirement for separate pre-licensing clinical trials and extensive drug-drug interaction studies" /><sentence text=" We review the global epidemiology, natural history and pathogenesis of chronic hepatitis C in HIV co-infection" /><sentence text=" The accelerated course of chronic hepatitis C in HIV co-infection is not adequately offset by successful combination antiretroviral therapy" /><sentence text=" We also review the treatment trials of chronic hepatitis C in HIV co-infected individuals with DAAs and compare them to trials in the HCV mono-infected" /><sentence text=" There is convincing evidence that HIV co-infection no longer diminishes the response to treatment against HCV in the new era of DAA-based therapy" /><sentence text=" The management of HCV co-infection should therefore become a priority in the care of HIV infected individuals, along with public health efforts to prevent new HCV infections, focusing particularly on specific patient groups at risk, such as men who have sex with men and injecting drug users" /><sentence text=" " /></document>